Drugs for Gallbladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 169)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Sevoflurane |
Approved, Vet_approved |
Phase 4 |
|
28523-86-6 |
5206 |
Synonyms:
1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
Fluoromethyl hexafluoroisopropyl ether
Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
HFE-347MMZ1
MR6S4
MR-6S4
Sevofluran
SEVOFLURANE
|
Sevoflurano
Sevoflurano [INN-Spanish]
Sevofluranum
Sevofluranum [INN-Latin]
Sevorane
SOJOURN
Ultane
|
|
2 |
|
Desflurane |
Approved |
Phase 4 |
|
57041-67-5 |
42113 |
Synonyms:
(+-)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
(±)-2-difluoromethyl 1,2,2,2-tetrafluoroethyl ether
1,1,1,2-Tetrafluoro-2-(difluoromethoxy)ethane
1,2,2,2-Tetrafluoroethyl difluoromethyl ether
Baxter anaesthesia brand OF desflurane
Baxter brand OF desflurane
DESFLURANE
DESFLURANO
Desflurano [INN-Spanish]
|
DESFLURANUM
Desfluranum [INN-Latin]
Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
HFE-236EA2
I-653
Ohmeda brand OF desflurane
Suprane
Zeneca brand OF desflurane
|
|
3 |
|
Platelet Aggregation Inhibitors |
|
Phase 4 |
|
|
|
4 |
|
Anesthetics, Inhalation |
|
Phase 4 |
|
|
|
5 |
|
Anesthetics, General |
|
Phase 4 |
|
|
|
6 |
|
Anesthetics |
|
Phase 4 |
|
|
|
7 |
|
Ulipristal acetate |
|
Phase 4 |
|
126784-99-4 |
13559282 130904 |
Synonyms:
(11BETA,17ALPHA)-17-ACETYL-11-[4-(DIMETHYLAMINO)PHENYL]-3-OXOESTRA-4,9-DIEN-17-YL ACETATE
14-Acetyl-17-[4-(dimethylamino)phenyl]-15-methyl-5-oxotetracyclo[8.7.0.0,.0,]heptadeca-1,6-dien-14-yl acetic acid
17-ACETOXY-11-(4-N,N-DIMETHYLAMINOPHENYL)PREGNA-4,9-DIENE-3,20-DIONE
CDB 2914
CDB-2914
CDB-2914|EllaOne®|VA2914
ELLA
ELLAONE
|
ESMYA
PGL-4001
RTI-3021-012
ULIPRISTAL ACET
ULIPRISTAL ACETATE
Ulipristal acetic acid
VA2914
VA-2914
|
|
8 |
|
Epirubicin |
Approved |
Phase 3 |
|
56420-45-2 |
41867 |
Synonyms:
4' Epi adriamycin
4' Epi doxorubicin
4' Epi DXR
4' Epiadriamycin
4' Epidoxorubicin
4'-Epiadriamycin
4'-Epi-adriamycin
4'-Epidoxorubicin
4'-Epi-doxorubicin
4'-Epi-DXR
Cell pharm brand OF epirubicin
Ellence
EPI cell
Epiadriamycin
EPIcell
EPI-cell
Epidoxorubicin
Epi-Dx
Epilem
Epirubicin
Epirubicin hydrochloride
Epirubicina
Epirubicina [INN-Spanish]
Epirubicina [Spanish]
Epirubicine
|
Epirubicine [French]
Epirubicine [INN-French]
Epirubicinum
Epirubicinum [INN-Latin]
Epirubicinum [Latin]
Farmorubicin
Farmorubicina
Farmorubicine
Hydrochloride, epirubicin
IMI 28
IMI28
IMI-28
Kenfarma brand OF epirubicin hydrochloride
Lemery brand OF epirubicin hydrochloride
NSC-256942
Pfizer brand OF epirubicin hydrochloride
Pharmorubicin
Pharmorubicin Pfs
Pidorubicina
Pidorubicina [INN-Spanish]
Pidorubicine
Pidorubicine [INN-French]
Pidorubicinum
Pidorubicinum [INN-Latin]
Ridorubicin
|
|
9 |
|
Somatostatin |
Approved, Investigational |
Phase 3 |
|
38916-34-6, 51110-01-1 |
53481605 16129706 |
Synonyms:
(5S,8R,14R,17R,20R,23R,26R,29R,32R,35R)-38-[(2-{[(2R)-2-amino-1-hydroxypropylidene]amino}-1-hydroxyethylidene)amino]-20,35-bis(4-aminobutyl)-14,26,29-tribenzyl-7,10,13,16,19,22,25,28,31,34,37-undecahydroxy-32-[(C-hydroxycarbonimidoyl)methyl]-11-(1-hydroxyethyl)-17-[(1S)-1-hydroxyethyl]-8-(hydroxymethyl)-23-[(1H-indol-3-yl)methyl]-1,2-dithia-6,9,12,15,18,21,24,27,30,33,36-undecaazacyclononatriaconta-6,9,12,15,18,21,24,27,30,33,36-undecaene-5-carboxylate
ALA-GLY-CYCLO-[CYS-LYS-ASN-PHE-PHE-TRP-LYS-THR-PHE-THR-SER-CYS]
Growth hormone-inhibiting hormone (ghih)
L-ALANYLGLYCYL-L-CYSTEINYL-L-LYSYL-L-ASPARAGINYL-L-PHENYLALANYL-L-PHENYLALANYL-L-TRYPTOPHYL-L-LYSYL-L-THREONYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-CYSTEINE CYCLIC (3-14) DISULFIDE
SOMATOSTATIN
SOMATOSTATIN-1
SOMATOSTATIN-14
SOMATOSTATINA
|
SOMATOSTATINE
SOMATOSTATINUM
Somatotropin release-inhibiting factor (srif)
Somatotropin release-inhibiting hormone
SRIF-14
SYNTHETIC GROWTH HORMONE RELEASE-INHIBITING HORMONE
SYNTHETIC SOMATOSTATIN-14
|
|
10 |
|
Magnesium sulfate |
Approved, Investigational, Vet_approved |
Phase 3 |
|
7487-88-9 |
|
Synonyms:
Magnesium sulfate (1:1)
Magnesium sulfate anhydrous
Magnesium sulphate
|
magnesium(II) sulfate
Magnesiumsulfat
MgSO4
|
|
11 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2, Phase 3 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
12 |
|
Citalopram |
Approved |
Phase 3 |
|
59729-32-7, 59729-33-8 |
2771 |
Synonyms:
[<sup>3</sup>H]-citalopram
Akarin
Bonitrile
Celapram
Celexa
Celexa®|Cipramil®|LU-10171B
Celius
Ciazil
Cilift
Cipram
CIPRAMIL
Ciprapine
Citabax
Citadur
Citalec
Citalopram
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
Citol
Citopam
Citox
|
Citrol
Cytalopram
Dalsan
Elopram
Escitalopram
Escitalopram oxalate
Humorup
Lexapro
LU 10-171-B
LU-10-171-B
Nitalapram
Oropram
PAXORAN
Pramcit
Recital
Seropram
Talam
Talohexal
Temperax
Vodelax
Zentius
Zetalo
|
|
13 |
|
Dexetimide |
Withdrawn |
Phase 3 |
|
21888-98-2 |
30843 |
Synonyms:
(+)-BENZETIMIDE
(+)-benzetimide|R 16470|Tremblex®
Dexetimida
DEXETIMIDE
|
Dexetimidum
R 16470
R-16470 [AS HYDROCHLORIDE]
TREMBLEX
|
|
14 |
|
Anti-Bacterial Agents |
|
Phase 3 |
|
|
|
15 |
|
Antibiotics, Antitubercular |
|
Phase 3 |
|
|
|
16 |
|
Emetics |
|
Phase 3 |
|
|
|
17 |
|
Hormone Antagonists |
|
Phase 3 |
|
|
|
18 |
|
Mitogens |
|
Phase 2, Phase 3 |
|
|
|
19 |
|
Albumin-Bound Paclitaxel |
|
Phase 2, Phase 3 |
|
|
|
20 |
|
Antimitotic Agents |
|
Phase 2, Phase 3 |
|
|
|
21 |
|
Tubulin Modulators |
|
Phase 2, Phase 3 |
|
|
|
22 |
|
Cola |
|
Phase 3 |
|
|
|
23 |
|
Parasympatholytics |
|
Phase 3 |
|
|
|
24 |
|
Antiparkinson Agents |
|
Phase 3 |
|
|
|
25 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
26 |
|
Psychotropic Drugs |
|
Phase 3 |
|
|
|
27 |
|
Antidepressive Agents |
|
Phase 3 |
|
|
|
28 |
|
Serotonin Uptake Inhibitors |
|
Phase 3 |
|
|
|
29 |
|
Muscarinic Antagonists |
|
Phase 3 |
|
|
|
30 |
|
Cholinergic Antagonists |
|
Phase 3 |
|
|
|
31 |
|
Cholinergic Agents |
|
Phase 3 |
|
|
|
32 |
|
Serotonin |
Investigational, Nutraceutical |
Phase 3 |
|
50-67-9 |
5202 |
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5 Hydroxytryptamine
5-HT
5-HT|serotonin
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
5-Hydroxy-tryptamine
|
Antemovis
DS Substance
Enteramin
Enteramine
Hippophaine
Hydroxytryptamine
SEROTONIN
Serotonine
sérotonine
Thrombocytin
Thrombotonin
|
|
33 |
|
Cetuximab |
Approved |
Phase 2 |
|
205923-56-4 |
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
34 |
|
Everolimus |
Approved |
Phase 2 |
|
159351-69-6 |
70789204 6442177 |
Synonyms:
001, RAD
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-HYDROXYETHYL)RAPAMYCIN
Afinitor
AFINITOR DISPERZ
Afinitor®|Certican®|RAD-001|RAD001|rapamycin, 42-O-(2-hydroxyethyl)-|Zortress®
Certican
EVEROLIMUS
évérolimus
RAD 001
|
RAD 666
RAD, SDZ
RAD001
RAD-001
RAD-666
SDZ RAD
SDZ-RAD
VOTUBIA
ZORTRESS
|
|
35 |
|
Gefitinib |
Approved, Investigational |
Phase 2 |
|
184475-35-2 |
123631 |
Synonyms:
4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
GEFITINIB
Gefitinibum
Iressa
Iressa®|ZD 1839|ZD1839
Irressat
|
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide
N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine
ZD 1839
ZD1839
ZD-1839
|
|
36 |
|
Crizotinib |
Approved, Investigational |
Phase 2 |
|
877399-52-5 |
11626560 |
Synonyms:
(<i>R</i>)-crizotinib|PF 2341066|PF-02341066|PF-2341066|PF2341066|Xalkori®
(R)-CRIZOTINIB
CRIZOTINIB
Crizotinibum
PF 2341066
|
PF-02341066
PF2341066
PF-2341066
XALKORI
|
|
37 |
|
Lenograstim |
Approved, Investigational |
Phase 2 |
|
135968-09-1 |
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
GRANOCYTE-13
GRANOCYTE-34
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
RG-CSF
|
|
38 |
|
Doxorubicin |
Approved, Investigational |
Phase 2 |
|
23214-92-8 |
31703 |
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
ADM
ADR
Adriablastin
Adriablastine
Adriamycin
Adriamycin PFS
Adriamycin RDF
Adriamycin Semiquinone
Adriamycin®|Caelyx® (liposomal doxorubicin)|Doxil®|doxorubicin hydrochloride
Adriblastin
Adriblastina
Adriblastine
Adrimedac
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
Bristol-myers squibb brand OF doxorubicin hydrochloride
Caelyx
Cell pharm brand OF doxorubicin hydrochloride
Columbia brand OF doxorubicin hydrochloride
DM2
DOXIL
Doxo
Doxo cell
Doxo-cell
Doxolem
DOXORUBICIN
Doxorubicin HCl
Doxorubicin hexal
Doxorubicin hydrochloride
|
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
Elan brand OF doxorubicin hydrochloride
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
Hexal brand OF doxorubicin hydrochloride
Hydrochloride, doxorubicin
HYDROXYDAUNORUBICIN
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
Medac brand OF doxorubicin hydrochloride
Myocet
Neocorp brand OF doxorubicin hydrochloride
NSC-123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Tedec meiji brand OF doxorubicin hydrochloride
Urokit doxo cell
Urokit doxo-cell
VALRUBICIN IMPURITY, DOXORUBICIN
|
|
39 |
|
Apixaban |
Approved |
Phase 2 |
|
503612-47-3 |
10182969 |
Synonyms:
APIXABAN
APIXABÁN
Apixabanum
BMS 562247-01
|
BMS-562247
BMS-562247|Eliquis®
BMS-562247-01
Eliquis
|
|
40 |
|
Rivaroxaban |
Approved |
Phase 2 |
|
366789-02-8 |
9875401 |
Synonyms:
BAY 59-7939
BAY 59-7939|Xarelto®
BAY59-7939
BAY-59-7939
|
JNJ39039039
JNJ-39039039
RIVAROXABAN
XARELTO
|
|
41 |
|
Heparin, bovine |
Approved, Investigational, Withdrawn |
Phase 2 |
|
9005-49-6 |
22833565 9812414 772 |
Synonyms:
Adomiparin
alpha-Heparin
Ariven
Arteven
Bemiparin
BOVINE HEPARIN
Calcilean
CALCIPARINE
Certoparin
CLEXANE
Clexane®|enoxaparin sodium|Lovenox®|PK-10169|RP-54563
Clivarin
Clivarine
DALTEPARIININATRIUM
Dalteparin
DALTEPARIN SODIUM
dalteparin sodium|Fragmin®
DALTEPARIN SODNÁ SŮL
DALTEPARIN SODYUM
DALTEPARINA SODICA
DALTEPARINA SÓDICA
DALTEPARINE SODIQUE
DALTÉPARINE SODIQUE
DALTEPARINNATRIUM
DALTEPARIN-NATRIUM
DALTEPARIN-NÁTRIUM
DALTEPARINO NATRIO DRUSKA
DALTEPARINUM NATRICUM
DALTEPARYNA SODOWA
Depo-Heparin
ENOXAPARIN
ENOXAPARIN SODIUM
ENOXAPARIN SODIUM (PRESERVATIVE FREE)
ENOXAPARIN SODIUM SALT
Eparina
Eparina [DCIT]
Fluxum
FR-860
FRAGMIN
Fragmin A
Fragmin B
Fraxiparin
Hed-Heparin
Hepalean
HEPARIN
Heparin Cy 216
|
HEPARIN FRAGMENT KABI 2165
Heparin Leo
Heparin Lock Flush
HEPARIN SODIUM
Heparin sodium preservative Free
Heparin sodium salt
Heparin sulfate
Heparin sulphate
Heparina
HEPARINATE
Heparine
HEPARINIC ACID
Heparinsodiumsalt
Heparinum
Hepathrom
HepFlush®
HEP-LOCK
KABI-2165
Leparan
Lipo-Hepin
LIQUAEMIN
Liquaemin Sodium
Liquemin
LOVENOX
LOVENOX (PRESERVATIVE FREE)
LOW LIQUEMINE
Low molecular weight heparin sodium
Multiparin
Novoheparin
Pabyrin
PANHEPRIN
Parnaparin
Parnaparin sodium
Parvoparin
PK-10169
Pularin
Reviparin
RP-54563
Sandoparin
SODIUM HEPARIN
Sublingula
TEDELPARIN
Thromboliquine
Unfractionated heparin
Vetren
Vitrum AB
|
|
42 |
|
Reviparin |
Approved, Investigational |
Phase 2 |
|
9041-08-1 |
|
Synonyms:
INNOHEP
Innohep®|tinzaparin sodium
LNH1
LNH-1
LOGIPARIN
|
Reviparin sodium
TINZAPARIN
Tinzaparin sodium
Tinzaparina
|
|
43 |
|
Cannabidiol |
Approved, Investigational |
Phase 1, Phase 2 |
|
13956-29-1 |
521372 644019 |
Synonyms:
(−)-trans-2-p-mentha-1,8-dien-3-yl-5-pentylresorcinol
(−)-trans-cannabidiol
(1'R,2'R)-5'-methyl-4-pentyl-2'-(prop-1-en-2-yl)-1',2',3',4'-tetrahydrobiphenyl-2,6-diol
BTX-1503
CANNABIDIOL
CBD
CBD|Epidiolex®|GWP42003-P|nabiximols (CBD + THC, fixed-dose oral spray)|Sativex® (CBD + THC, fixed-dose oral spray)
|
EPIDIOLEX
GWP42003
GWP-42003
GWP42003-P
GWP-42003-P
Δ1(2)-trans-cannabidiol
|
|
44 |
|
Temozolomide |
Approved, Investigational |
Phase 1, Phase 2 |
|
85622-93-1 |
5394 |
Synonyms:
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-D)-1,2,3,5-tetrazine-8-carboxamide
3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-D)-as-tetrazine-8-carboxamide
3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-D)(1,2,3,5)tetrazine-8-carboxamide
8-Carbamoyl-3-methylimidazo(5,1-D)-1,2,3,5-tetrazin-4(3H)-one
BRN 5547136
CCRG 81045
CCRG-81045
CCRIS 8996
m & b 39831
m And b 39831
m And b39831
m And b-39831
M&B 39831
M&B-39831
M-39831
MB 39831
Methazolastone
NSC 362856
NSC-362856
|
SCH 52365
SCH-52365
Temodal
Temodar
TEMOMEDAC
Temozolamide
Temozolodida
Temozolodida [Spanish]
Temozolomid
Temozolomida
Temozolomide
Témozolomide
Temozolomide hexyl ester
Temozolomidum
Temozolomidum [Latin]
TMZ
TMZ Bioshuttle
TMZA-he
TMZ-Bioshuttle
|
|
45 |
|
Ramucirumab |
Approved, Investigational |
Phase 2 |
|
947687-13-0 |
|
Synonyms:
1121B
CYRAMZA
Cyramza®|IMC-1121B
|
IMC-1121B
LY3009806
Ramucirumab
|
|
46 |
|
Trametinib |
Approved |
Phase 2 |
|
871700-17-3 |
11707110 |
Synonyms:
GSK 1120212
GSK1120212
GSK-1120212
GSK1120212|GSK1120212B|GSK212|JTP 74057|Mekinist®|trametinib dimethyl sulfoxide
GSK1120212B
GSK212
JTP 74057
|
JTP-74057
MEKINIST
TMT212
TRAMETINIB
TRAMÉTINIB
TRAMETINIB DIMETHYL SULFOXIDE
TRAMETINIBUM
|
|
47 |
|
Lapatinib |
Approved, Investigational |
Phase 2 |
|
231277-92-2, 388082-78-8 |
208908 |
Synonyms:
FMM
FMM|GW 572016|GW572016|Tykerb®|Tyverb®
GSK-572016
GW 572016
GW-2016
GW572016
GW-572016
GW572016F
GW-572016F
GW-572016X
LAP016
LAPATINIB
LAPATINIB DITOLUENESULFONATE MONOHYDRATE
|
Lapatinib ditosylate
LAPATINIB DITOSYLATE MONOHYDRATE
Lapatinib tosilate hydrate
N-(3-Chloro-4-(((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-methylsulfonyl)ethyl)amino)methyl) -2-furyl)-4-quinazolinamine
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulphonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
N-{3-CHLORO-4-[(3-FLUOROPHENYL)METHOXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURANYL]-4-QUINAZOLINAMINE
Tycerb
Tykerb
TYVERB
|
|
48 |
|
Panitumumab |
Approved, Investigational |
Phase 2 |
|
339177-26-3 |
|
Synonyms:
ABX-EGF
ABX-EGF|ABX-EGF Mab|Vectibix®
E7.6.3
|
L01XC08
PANITUMUMAB
VECTIBIX
|
|
49 |
|
Pemetrexed |
Approved, Investigational |
Phase 1, Phase 2 |
|
150399-23-8, 137281-23-3 |
60843 446556 135565230 |
Synonyms:
(2R)-2-{[4-(2-{4-hydroxy-2-imino-1H,2H,7H-pyrrolo[2,3-D]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioate
ALIMTA
Alimta®|LY-231514
Disodium, pemetrexed
LY-2315
LY231514
|
LY-231514
MTA
N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-D)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
NSC-698037
Pemetrexed
Pemetrexed disodium
|
|
50 |
|
Oxaliplatin |
Approved, Investigational |
Phase 1, Phase 2 |
|
61825-94-3 |
43805 11947679 6857599 |
Synonyms:
ACT 078
ACT-078
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatine
Elplat
Foloxatine
JM-83
L-OHP
L-OHP CPD
MBP-426 (LIPOSOMAL OXALIPLATIN)
NSC-266046
Oxalatoplatin
|
Oxalatoplatinum
Oxaliplatin
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
RP-54780
SR-96669
Transplatin
|
|
Interventional clinical trials:
(show top 50)
(show all 195)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study |
Unknown status |
NCT02174575 |
Phase 4 |
Sevoflurane;Desflurane |
2 |
Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study. |
Completed |
NCT00280709 |
Phase 4 |
|
3 |
Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma |
Unknown status |
NCT02798510 |
Phase 3 |
capecitabine;gemcitabine |
4 |
A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy. |
Completed |
NCT01926236 |
Phase 3 |
L-folinic acid;5 FU;Oxaliplatin |
5 |
Effect of Palliative Biliary Stenting Versus Conservative Treatment on the Quality of Life (QOL) of Patients With Unresectable Carcinoma of the Gallbladder With Hiliar Block: A Randomised Controlled Trial |
Completed |
NCT00391183 |
Phase 2, Phase 3 |
|
6 |
Porfimer Sodium Photodynamic Therapy Plus Stenting Versus Stenting Alone in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumours: a Multicentre, Randomised, Phase Lll Study |
Completed |
NCT00513539 |
Phase 3 |
porfimer sodium |
7 |
Phase III Randomized Controlled Trial of a Collaborative Care Intervention to Manage Cancer Related Symptoms in Patients Diagnosed With Hepatobiliary Carcinoma |
Completed |
NCT01640522 |
Phase 3 |
|
8 |
Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study |
Completed |
NCT00262769 |
Phase 3 |
cisplatin;gemcitabine hydrochloride |
9 |
A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer |
Completed |
NCT00363584 |
Phase 3 |
capecitabine |
10 |
Randomized Phase II-III Study of Chemoradiation With Fluorouracil and Cisplatin Versus Chemotherapy (Gemcitabine/Oxaliplatin) in Non Resectable But Non Metastatic Cancer of the Biliary Tract |
Completed |
NCT00304135 |
Phase 2, Phase 3 |
cisplatin;gemcitabine hydrochloride;oxaliplatin |
11 |
Phase III Multicenter Randomized Study Comparing the Effect of Adjuvant Chemotherapy for Six Months With Gemcitabine-Oxaliplatin 85 mg/m2 (GEMOX 85) to Observation in Patients Who Underwent Surgery for Cancer of the Bile Ducts |
Completed |
NCT01313377 |
Phase 3 |
gemcitabine hydrochloride;oxaliplatin |
12 |
A Phase III Study of New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma |
Completed |
NCT01053390 |
Phase 3 |
Somatostatin;epirubicin, cisplatin, LV(Leucovorin)、 5-FU(5-Fluorouracil) |
13 |
Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial |
Recruiting |
NCT04559139 |
Phase 2, Phase 3 |
Cisplatin;Gemcitabine Hydrochloride |
14 |
Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC (ICC/ECC) - A Phase III Study of the German Registry of Incidental Gallbladder Carcinoma Platform (GR) - The AIO/ CALGP/ ACO- GAIN-Trial - |
Recruiting |
NCT03673072 |
Phase 3 |
Gemcitabine;Cisplatin;Adjuvant chemotherapy |
15 |
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial) |
Recruiting |
NCT02170090 |
Phase 3 |
Gemcitabine;Cisplatin;Capecitabine |
16 |
Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers |
Recruiting |
NCT02867865 |
Phase 2, Phase 3 |
Gemcitabine;Cisplatin |
17 |
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers |
Active, not recruiting |
NCT03768414 |
Phase 3 |
Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel |
18 |
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer |
Active, not recruiting |
NCT04066491 |
Phase 2, Phase 3 |
M7824;Placebo;Gemcitabine;Cisplatin |
19 |
A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen |
Not yet recruiting |
NCT05506943 |
Phase 2, Phase 3 |
CTX-009;Paclitaxel |
20 |
Symptom Management Trial in Cancer Survivors |
Terminated |
NCT00387348 |
Phase 3 |
escitalopram oxalate;Placebo |
21 |
A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) Versus Gemcitabine Alone in Advanced Biliary Cancer |
Terminated |
NCT00658593 |
Phase 3 |
capecitabine;gemcitabine hydrochloride |
22 |
Perioperative Chemotherapy Prior To and After Reoperation for Incidental Gallbladder Cancer - An International, Randomized Phase III Trial |
Withdrawn |
NCT03579758 |
Phase 3 |
Capecitabine;Cisplatin;Gemcitabine |
23 |
Phase III Randomized Study of Double Plastic Endoprosthesis Insertion With Versus Without Adjuvant Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Patients With Unresectable Stage III-IV Cholangiocarcinoma |
Withdrawn |
NCT00253617 |
Phase 3 |
porfimer sodium |
24 |
A Randomized, Open, Prospective Clinical Research Programs of Fluorouracil Implant (Sinofuan) to Improve Surgical Gallbladder Cancer and Bile Duct Cancer |
Unknown status |
NCT01317069 |
Phase 2 |
Fluorouracil implant |
25 |
A Multicentre, Open-label, Randomised, Controlled Study of Molecularly Precision Target Therapy Based on Tumor Molecular Profiling With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma |
Unknown status |
NCT03768375 |
Phase 2 |
|
26 |
A Multicentre, Open-label, Randomised, Controlled Study of Molecularly Precision Target Therapy Based on Tumor Molecular Profiling With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma |
Unknown status |
NCT03772132 |
Phase 2 |
|
27 |
Phase II Study of TLC D-99 for Hepatobiliary Carcinomas |
Unknown status |
NCT00003296 |
Phase 2 |
pegylated liposomal doxorubicin hydrochloride |
28 |
Open One-Arm Therapy Optimizing Trial on Regional Chemotherapy of the Liver Through an Interventionally Implanted A.Hepatica Port System in Patients With Liver Metastases or Primary Liver Neoplasms. |
Unknown status |
NCT00356161 |
Phase 2 |
|
29 |
A Multicentre, Open-label, Randomised, Controlled Study of Molecularly Precision Target Therapy Based on Tumor Molecular Profiling With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma |
Unknown status |
NCT02836847 |
Phase 2 |
GEMOX;Cetuximab;Trastuzumab;Gefitinib;Lapatinib;Everolimus;Sorafenib;Crizotinib |
30 |
A Single-center Open, Randomized, Controlled Study to Compare the Apapitatin Combined With SOX and SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcinoma |
Unknown status |
NCT03702491 |
Phase 2 |
Apatinib;Tegafur |
31 |
A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism in Patients With Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY |
Unknown status |
NCT03139487 |
Phase 2 |
Rivaroxaban;Dalteparin;apixaban |
32 |
Randomized Double-Blind, Placebo-Controlled Parallel Multi-Center Study to Assess the Efficacy of Cannabidiol (BRCX014) Combined With Standard-Of-Care Treatment in Subjects With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies |
Unknown status |
NCT03607643 |
Phase 1, Phase 2 |
Cannabidiol;Bortezomib;Leucovorin;5-FU;Oxaliplatin;Bevacizumab;Irinotecan;Gemcitabine;Temozolomide |
33 |
A Phase II Study of Ramucirumab for Advanced, Pre-Treated Biliary Cancers |
Completed |
NCT02520141 |
Phase 2 |
|
34 |
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer |
Completed |
NCT02042443 |
Phase 2 |
Capecitabine;Fluorouracil;Leucovorin Calcium;Trametinib |
35 |
A Phase II Study of Triapine in Combination With Gemcitabine in Adenocarcinoma of the Biliary Ducts and Gall Bladder |
Completed |
NCT00075504 |
Phase 2 |
triapine;gemcitabine |
36 |
A Phase II Study of Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers |
Completed |
NCT02392637 |
Phase 2 |
Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel |
37 |
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies |
Completed |
NCT02333188 |
Phase 1, Phase 2 |
Paclitaxel Albumin-Stabilized Nanoparticle Formulation;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil |
38 |
A Phase II Study of GW572016 (Lapatanib) in Locally Advanced or Metastatic Hepato-Biliary Cancers |
Completed |
NCT00101036 |
Phase 2 |
lapatinib ditosylate |
39 |
A Phase II Trial of OSI-774 in Patients With Hepatocellular or Biliary Carcinoma |
Completed |
NCT00033462 |
Phase 2 |
erlotinib hydrochloride |
40 |
A Phase II Trial of Bevacizumab and Erlotinib in Patients With Advanced Biliary Tumors |
Completed |
NCT00356889 |
Phase 2 |
erlotinib hydrochloride |
41 |
Phase II Study of BAY 43-9006 (NSC #724772) as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma |
Completed |
NCT00238212 |
Phase 2 |
sorafenib tosylate |
42 |
A Phase II Study of Efficacy and Tolerability of GW572016 in Patients With Advanced Hepatocellular and Biliary Carcinomas |
Completed |
NCT00107536 |
Phase 2 |
lapatinib ditosylate |
43 |
A Phase II Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer |
Completed |
NCT00660140 |
Phase 2 |
Gemcitabine;Carboplatin |
44 |
A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in Combination With Gemcitabine Versus Gemcitabine Plus Vandetanib Matching Placebo in Subjects With Advanced Biliary Tract Cancer (Gallbladder Cancer, Cancer of the Extrahepatic Bile Duct, Intrahepatic Cholangiocarcinoma and Ampullary Carcinoma) |
Completed |
NCT00753675 |
Phase 2 |
ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474 |
45 |
A Phase II Trial of Gemcitabine and Cisplatin In Unresectable Or Metastatic Biliary Tract and Gallbladder Cancer |
Completed |
NCT00123825 |
Phase 2 |
Gemcitabine;Cisplatin |
46 |
Phase II Study of Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Biliary Tract and Gallbladder Cancer |
Completed |
NCT00142480 |
Phase 2 |
Capecitabine;Oxaliplatin;Bevacizumab |
47 |
A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Biliary Tree Cancer (Cholangiocarcinoma and Gallbladder Cancer) |
Completed |
NCT00005938 |
Phase 2 |
exatecan mesylate |
48 |
Phase II Study of Gemcitabine, Oxaliplatin in Combination With Bevacizumab (Avastin) in Unresectable or Metastatic Biliary Tract and Gallbladder Cancer |
Completed |
NCT00361231 |
Phase 2 |
Bevacizumab;Gemcitabine;Oxaliplatin |
49 |
Phase II Study of Gemcitabine, Oxaliplatin in Combination With Panitumumab in Kras/B-raf Wild-Type Unresectable or Metastatic Biliary Track and Gallbladder Cancer |
Completed |
NCT01308840 |
Phase 2 |
Panitumumab;oxaliplatin;gemcitabine |
50 |
A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed By Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC) |
Completed |
NCT00789958 |
Phase 2 |
capecitabine;gemcitabine hydrochloride |
|